Jordan M Cloyd1, Aslam Ejaz1, Timothy M Pawlik2,3. 1. Department of Surgery, The Ohio State University, Columbus, OH, USA. 2. Department of Surgery, The Ohio State University, Columbus, OH, USA. tim.pawlik@osumc.edu. 3. Department of Surgery, Oncology, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, Health Services Management and Policy, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. tim.pawlik@osumc.edu.
Abstract
INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) is an aggressive biliary tract cancer (BTC) with distinct anatomic, molecular, and clinical characteristics that distinguishes it from other BTCs. METHODS: In this landmark series review, we highlight the critical studies that have defined the surgical management of ICC, as well as several randomized controlled trials that have investigated adjuvant therapy strategies. RESULTS: Surgical resection is the mainstay of treatment and should involve margin-negative resection with regional lymphadenectomy. Several recently completed and ongoing randomized controlled trials are defining the indications for adjuvant therapy among patients with resected ICC. CONCLUSIONS: In the near future, improved understanding of the molecular features of ICC should lead to newer targeted therapies as well as a more personalized approach to systemic therapy.
INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is an aggressive biliary tract cancer (BTC) with distinct anatomic, molecular, and clinical characteristics that distinguishes it from other BTCs. METHODS: In this landmark series review, we highlight the critical studies that have defined the surgical management of ICC, as well as several randomized controlled trials that have investigated adjuvant therapy strategies. RESULTS: Surgical resection is the mainstay of treatment and should involve margin-negative resection with regional lymphadenectomy. Several recently completed and ongoing randomized controlled trials are defining the indications for adjuvant therapy among patients with resected ICC. CONCLUSIONS: In the near future, improved understanding of the molecular features of ICC should lead to newer targeted therapies as well as a more personalized approach to systemic therapy.
Authors: Mechteld C de Jong; Hari Nathan; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; T Clark Gamblin; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Richard D Schulick; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik Journal: J Clin Oncol Date: 2011-07-05 Impact factor: 44.544
Authors: John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores Journal: J Hepatol Date: 2014-03-27 Impact factor: 25.083
Authors: Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores Journal: Nat Rev Clin Oncol Date: 2017-10-10 Impact factor: 66.675
Authors: Xu-Feng Zhang; Fabio Bagante; Jeffery Chakedis; Dimitrios Moris; Eliza W Beal; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-07-25 Impact factor: 3.452
Authors: Gaya Spolverato; Mohammad Y Yakoob; Yuhree Kim; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; J Wallis Marsh; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2015-03-12 Impact factor: 5.344
Authors: Yao Xiao; Baoluhe Zhang; Jordan M Cloyd; Laura Alaimo; Gang Xu; Shunda Du; Yilei Mao; Timothy M Pawlik Journal: Cancers (Basel) Date: 2022-07-05 Impact factor: 6.575
Authors: Tao Wang; Jinfu Zhang; Wanxiang Wang; Xianwei Yang; Junjie Kong; Shu Shen; Wentao Wang Journal: Cancer Manag Res Date: 2020-11-02 Impact factor: 3.989